StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Chandan Taparia, Motilal Oswal

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))12 Oct 2026via CNBC Awaaz.

Entry₹1,200Inferred
Target₹1,245
Total upside +3.75%
Stop loss₹1,195-0.42% risk
CMP₹1,229.4Just now
Active+2.45%+1.27%upside left 14d left
Follow Chandan Taparia for new calls(32% target hit, 230 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 1 other Swing call on DRREDDYSee 83 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 12 Oct, 4:45 pm IST
7 supporting1 neutral4 opposing
Supports the BUY call (7)

MACD above its signal line — bullish momentum

Technicals · macd·12 Oct · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·12 Oct · today

Citi raises target for Dr Reddy's Laboratories stock to INR 1,450

NewsGoogle News·2 Oct · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories stock gets a Citi upgrade to Buy

NewsGoogle News·1 Oct · 2w ago

(opens in new tab)

Dr. Reddy's Laboratories stock gets a Citi upgrade as margins face a test

NewsGoogle News·30 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Q2 FY27 results scheduled — board meets 23 Oct 2026

BSE · Board Meeting·In 11 days

(opens in new tab)
Weighs against the BUY call (4)

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 3d ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 3d ago

(opens in new tab)

Dr. Reddy's USFDA PAI Inspection: Form 483 at FTO-11 Plant

NewsGoogle News·8 Oct · 4d ago

(opens in new tab)

Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked losses

NewsGoogle News·8 Oct · 4d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Chandan Taparia, Motilal Oswal

Every call and its outcome